| SMPD1 Gene - Acid Sphingomyelinase | |
|---|---|
| infobox | 1(2005) |
| **SMPD1 Gene** | 2(2003) |
| Symbol | SMPD1 |
| Chromosomal Location | 11p15.4 |
| NCBI Gene ID | 6609 |
| OMIM | 257200 |
| Ensembl ID | ENSG00000166311 |
| UniProt | P17405 |
| Associated Diseases | Niemann-Pick Disease Type A/B, Acid Sphingomyelinase Deficiency (ASMD) |
Pathway Diagram
flowchart TD
SMPD1["SMPD1"]
style SMPD1 fill:#006494,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0
Parkinson_s_disease["Parkinson's disease"]
SMPD1 -->|"contributes to"| Parkinson_s_disease
_middle_temporal_gyrus__spiny_["'middle temporal gyrus'_spiny_L3"]
SMPD1 -->|"expressed in"| _middle_temporal_gyrus__spiny_
_middle_temporal_gyrus__aspiny["'middle temporal gyrus'_aspiny_L3"]
SMPD1 -->|"expressed in"| _middle_temporal_gyrus__aspiny
SMPD1 -->|"expressed in"| _middle_temporal_gyrus__spiny_
neurodegeneration["neurodegeneration"]
SMPD1 -->|"associated with"| neurodegeneration
Parkinson["Parkinson"]
SMPD1 -->|"associated with"| Parkinson
Als["Als"]
SMPD1 -->|"associated with"| Als
Aging["Aging"]
SMPD1 -->|"associated with"| Aging
h_de0d4364["h-de0d4364"]
h_de0d4364 -->|"therapeutic target"| SMPD1
h_de0d4364 -->|"targets gene"| SMPD1
h_de0d4364 -->|"targets"| SMPD1
style Parkinson_s_disease fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
style _middle_temporal_gyrus__spiny_ fill:#888,stroke:#4fc3f7,color:#e0e0e0
style _middle_temporal_gyrus__aspiny fill:#888,stroke:#4fc3f7,color:#e0e0e0
style neurodegeneration fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
style Parkinson fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
style Als fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
style Aging fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
style h_de0d4364 fill:#888,stroke:#4fc3f7,color:#e0e0e0Introduction
Smpd1 Gene Acid Sphingomyelinase is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
SMPD1 (Sphingomyelin Phosphodiesterase 1) encodes acid sphingomyelinase (ASM), a lysosomal enzyme that hydrolyzes sphingomyelin to ceramide and phosphorylcholine. Mutations in SMPD1 cause Niemann-Pick disease types A and B, lysosomal storage disorders characterized by sphingomyelin accumulation in macrophages throughout the reticuloendothelial system. 3(1984)
Function
The SMPD1 gene encodes acid sphingomyelinase (ASM), a lysosomal hydrolase enzyme that catalyzes the hydrolysis of sphingomyelin to ceramide and phosphorylcholine. This enzyme plays a critical role in lipid metabolism and cellular signaling within the lysosomal compartment.
ASM is synthesized as a preproenzyme in the endoplasmic reticulum, processed through the Golgi apparatus, and targeted to lysosomes via mannose-6-phosphate receptor-mediated trafficking. The mature enzyme is a 75 kDa glycoprotein consisting of an N-terminal catalytic domain and a C-terminal domain.
Key Functions
-
Lipid Catabolism: Hydrolyzes sphingomyelin, a major membrane phospholipid, within lysosomes
-
Ceramide Generation: Produces ceramide, a bioactive lipid that regulates apoptosis, cell cycle arrest, and stress responses
-
Membrane Trafficking: Participates in endocytic and autophagic pathways
-
Signal Transduction: Ceramide generated by ASM acts as a second messenger in various signaling cascades
Disease Associations
Niemann-Pick Disease Type A and B
Niemann-Pick disease type A (NPD-A) and type B (NPD-B) are caused by autosomal recessive mutations in the SMPD1 gene, resulting in deficient or absent acid sphingomyelinase activity.
-
NPD-Type A: Severe infantile neurovisceral form with neurodegeneration, hepatosplenomegaly, and early mortality (typically by age 2-3)
-
NPD-Type B: Chronic visceral form with primarily systemic manifestations, often surviving into adulthood
Neurodegeneration in ASMD
While NPD-A/B are classically lysosomal storage disorders, the accumulated sphingomyelin and secondary ceramide elevation contribute to neurodegeneration through:
-
Lysosomal Dysfunction: Accumulated lipids impair lysosomal function and autophagy
-
Oxidative Stress: Ceramide accumulation promotes ROS generation
-
Apoptosis Signaling: Ceramide is a pro-apoptotic molecule that activates caspase-dependent cell death
-
Neuroinflammation: Lipid accumulation activates microglia and astrocytes
Potential Links to Other Neurodegenerative Diseases
Research suggests altered sphingolipid metabolism may play roles in:
-
Alzheimer’s Disease: Aβ-induced ceramide elevation and ASM activation
-
Parkinson’s Disease: Altered sphingolipid profiles in PD patients
-
Multiple Sclerosis: ASM deficiency protective in mouse models
Expression
SMPD1 is expressed ubiquitously with highest expression in:
-
Liver
-
Spleen
-
Lung
-
Brain (neurons and glia)
-
Fibroblasts
In the brain, ASM is expressed in neurons, astrocytes, microglia, and oligodendrocytes, with particular importance in white matter tracts.
Therapeutic Targeting
Enzyme Replacement Therapy
-
Olipudase alfa (Xenpozyme): FDA-approved recombinant human ASM (rh-ASM) for ASMD
-
Reduces sphingomyelin accumulation in liver and spleen
-
Does not cross the blood-brain barrier, limiting effects on CNS manifestations
Small Molecule Approaches
-
Substrate reduction therapy: Reduce sphingomyelin synthesis
-
Ceramide analogs: Modulate ceramide-mediated signaling
-
Gene therapy: AAV-vector delivery to CNS (experimental)
Research Directions
-
Brain-targeted enzyme replacement
-
Small molecule chaperones to enhance mutant ASM activity
-
Gene therapy approaches for CNS involvement
See Also
-
Niemann-Pick Disease - Overview of NPD types
-
Acid Sphingomyelinase Deficiency - ASMD disorder
-
Lysosomal Storage Disorders - Category of metabolic diseases
-
Lipid Metabolism - Cellular lipid pathways
-
Ceramide Signaling - Bioactive lipid pathways
-
Apoptosis Pathway - Cell death mechanisms
External Links
Background
The study of Smpd1 Gene Acid Sphingomyelinase has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
References
- (2005)
- (2003)
- (1984)
Sister wikis (recently updated · no domain on this page)
- Agent Recipe: AI-for-Biology Closed-Loop with Reviewer Handoffs and Eval Contracts
- Agent Recipe: AI-for-Biology Closed-Loop with Reviewer Handoffs and Eval Contracts
- test
- JGBO-I27: Top 10 GBO Questions for Prioritization
- JGBO-I27: Top 10 GBO Questions for Prioritization
- Design Brief: Beta-test Evaluation Protocol for SciDEX v2 Design Trajectories
- Andy — Showcase Findings (auto-curated)
- Kris — Showcase Findings (auto-curated)
Recent activity here
No recent events touching this page.